TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01640249
Drug: LY3006072
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT01363193
Drug: Lean Body Weight-based heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = \[9270 x weight (kg)\] / \[6680+216 x BMI\] Female = \[9270 x weight (kg)\] / \[8780+244 x BMI\]
Study: NCT04982861
Drug: Suprax 100 MG in 5 mL Oral Suspension
Normalized name: Suprax 100 MG in 5 mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single dose of 5 mL of Suprax with 240 mL of water
Study: NCT01193777
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus followed by 1 L NS infusion over 12 hours.
Study: NCT00380874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03380429
Drug: RELVAR/BREO
Approvals — FDA: no, EMA: no, PMDA: no
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
Study: NCT02816736
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively.
Study: NCT02816736
Drug: LCZ696 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
Study: NCT01515423
Drug: PP3M 175 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Study: NCT01515423
Drug: PP3M 263 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Study: NCT01515423
Drug: PP3M 350 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Study: NCT01515423
Drug: PP3M 525 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Study: NCT01515423
Drug: PP1M 50 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Study: NCT01515423
Drug: PP1M 75 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Study: NCT01515423
Drug: PP1M 100 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Study: NCT01515423
Drug: PP1M 150 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Study: NCT01722708
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clindamycin 300 Milligrams\*2/Day for a week
Study: NCT01110018
Drug: GSK573719 (INHALATION POWDER)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
Study: NCT01459133
Drug: Technosphere® Insulin Inhalation System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Site, Single Subject use of Technosphere® Insulin Inhalation System
Study: NCT02452606
Drug: Stalevo®
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective.
Study: NCT02056223
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/Kg every 6 hours for three days
Study: NCT02056223
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 -5-5 mg/Kg once a day for three days
Study: NCT04535141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina
Study: NCT01268670
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive topical LET and oral ibuprofen.
Study: NCT02401269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01075789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
Study: NCT01932333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
Study: NCT01669291
Drug: Bravelle and Menopur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bravelle and Menopur are used for controlled ovarian stimulation (COH)
Study: NCT01669291
Drug: Agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
Study: NCT01669291
Drug: Antagonist
Normalized name: Purine antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
Study: NCT00007631
Drug: Tretinoin 0.1% cream or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00659191
Drug: GSK1265744
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00842673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match ST101 tablets
Study: NCT00122382
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
Study: NCT00748592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study: NCT01615367
Drug: Typically consists of at least one FDA-approved mood stabilizer
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
Study: NCT04935541
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Study: NCT01288079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
Study: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
Study: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
Study: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
Study: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
Study: NCT05976100
Drug: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
Study: NCT01036854
Drug: EUR-1025
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 24 mg, daily for 6 days
Study: NCT01036854
Drug: EUR-1025
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 8 mg, twice daily over 6 consecutive days
Study: NCT01036854
Drug: EUR-1025
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 8 mg, three times a day over 6 consecutive days
Study: NCT01036854
Drug: EUR-1025
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
Study: NCT03170544
Drug: MK-1092, 8.0 nmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study: NCT03170544
Drug: MK-1092, 16 nmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study: NCT03170544
Drug: MK-1092, 32 nmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study: NCT03170544
Drug: MK-1092, 64 nmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study: NCT03170544
Drug: Glargine 3.0 nmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glargine 3.0 nmol/kg, SC, as a single dose
Study: NCT03170544
Drug: Lispro 1.2 nmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.
Study: NCT03170544
Drug: Placebo to glargine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to glargine, SC, as a single dose
Study: NCT03170544
Drug: Placebo to MK-1092
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MK-1092, SC, as a single dose
Study: NCT02445716
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit.
Study: NCT02445716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
Study: NCT01622673
Drug: TUMS® Ultra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT01622673
Drug: MINTOX® Maximum Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT00443729
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study: NCT00443729
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study: NCT02126514
Drug: AZD3293
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 subjects will receive AZD3293
Study: NCT00443690
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rolofylline Pbo 30 mg IV QD; 3 days
Study: NCT02508337
Drug: XG-102
Normalized name: Ninjacof XG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Study: NCT02508337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Study: NCT01841684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for anacetrapib orally, once daily for 12 weeks
Study: NCT01576354
Drug: Prolonged-release Fampridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg tablet twice a day (every 12 hours), orally
Study: NCT01576354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
Study: NCT00659711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be placed on a placebo for 12 weeks.
Study: NCT02426502
Drug: Conversion to Advagraf
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
Study: NCT01809275
Drug: QBECO
Normalized name: Quinolinate Benzodiazepine Ester Compound
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01809275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03177824
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
Study: NCT03405831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
Study: NCT04464174
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Study: NCT04369391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT01797874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo arm
Study: NCT04881474
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
Study: NCT02352701
Drug: Noltec tab. 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10mg BID dosage form : delayed release tablet
Study: NCT02352701
Drug: Cravit Tab. 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500mg, BID dosage form : film coated tablet
Study: NCT01900769
Drug: Blood Volume Dilution
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01695616
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01037218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT04505670
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04505670
Drug: Topical Zinc Oxide
Normalized name: zinc oxide Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Zinc Oxide 20%
Study: NCT00897715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of placebo administered subcutaneously once a week for 12 weeks
Study: NCT03711097
Drug: Vanish XT Dental Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varnish will be applied to the front surface of the intervention upper central and lateral incisors
Study: NCT03630497
Drug: Comparison of BN201 treatment with Placebo
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose or Multiple Dose of BN201 IV administration
Study: NCT02881853
Drug: XmAb7195
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02881853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00513240
Drug: Erythropoetin
Normalized name: Erythropoetin zeta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
Study: NCT00513240
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~.
Study: NCT02695446
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral extended release minocycline
Study: NCT02386319
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gelatin capsules
Study: NCT02386319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT04324424
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of HMS5552 25mg
Study: NCT02954484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule containing lactose and MCC (no active ingredients).
Study: NCT02954484
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
Study: NCT04162743
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: take placebo oral tablet before polysomnography
Study: NCT00455403
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
Study: NCT02391688
Drug: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218387
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03525561
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.